Agilent Technologies (California, USA) has announced a strategic collaboration with Seoul National Hospital (Seoul, Korea). The collaboration will focus on the identification and verification of biomarkers to further the development of drugs. Under the agreement, the hospital’s department of medicine will use liquid chromatography–mass spectrometry (LC–MS) instrumentation from Agilent to further research in this area.
According to Professor Byung-Hee Oh, president and CEO of the hospital, there are gaps within the medical industry that limit the quality of care that can be provided to patients. He said: "One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases."
Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region, said: "We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers." He added: "Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries."
For more information please visit www.agilent.com